Connect with us

Hi, what are you looking for?

Business

Vigilare Wealth Management Reduces AbbVie Holdings by 15.4%

Vigilare Wealth Management has decreased its stake in AbbVie Inc. (NYSE: ABBV) by 15.4%, selling 429 shares during the second quarter of 2023. The firm’s latest filing with the Securities and Exchange Commission revealed that it now holds 2,356 shares of AbbVie, valued at approximately $437,000. This adjustment comes amid a broader trend of institutional investors altering their positions in the pharmaceutical giant.

Several notable investors have recently modified their stakes in AbbVie. For instance, First Hawaiian Bank increased its holdings by 0.8%, acquiring 60 additional shares to bring its total to 7,556 shares, worth about $1.4 million. In a more significant move, Narus Financial Partners LLC raised its stake by 25.3% in the first quarter, now owning 1,988 shares valued at $417,000. Highland Capital Management LLC also boosted its position by 6.3%, holding 46,853 shares now worth approximately $9.8 million.

Institutional investors collectively own 70.23% of AbbVie’s stock, indicating strong professional confidence in the company.

Insider Transactions Highlight Activity

In addition to changes in institutional holdings, AbbVie executives have engaged in notable insider transactions. On August 5, 2023, Executive Vice President Nicholas Donoghoe sold 13,295 shares at an average price of $198.51, totaling approximately $2.64 million. This sale reduced Donoghoe’s holdings to 58,247 shares, valued at around $11.56 million, reflecting an 18.58% decrease in his position.

Similarly, Executive Vice President Azita Saleki-Gerhardt sold 42,370 shares on August 12, 2023, at an average price of $198.42, amounting to about $8.41 million. Following this transaction, Saleki-Gerhardt owns 177,292 shares, valued at approximately $35.18 million, marking a 19.29% reduction in her holdings. Together, these transactions demonstrate significant insider activity at AbbVie.

AbbVie Performance and Future Outlook

AbbVie recently reported its earnings for the second quarter on July 31, 2023. The company posted earnings per share (EPS) of $2.97, which fell short of analysts’ expectations by $0.27. AbbVie recorded revenue of $15.42 billion, exceeding estimates of $14.93 billion, and exhibited a 6.6% increase in revenue compared to the same quarter last year.

Looking ahead, analysts forecast that AbbVie will achieve an EPS of $12.31 for the current year. The company also announced a quarterly dividend of $1.64, scheduled for payment on November 14, 2023, to shareholders on record as of October 15, 2023. The dividend represents an annualized rate of $6.56 and a yield of 2.8%.

Research analysts continue to weigh in on AbbVie, with several firms adjusting their price targets. Piper Sandler initiated coverage with an overweight rating and a target price of $231.00, while Evercore ISI revised its price objective upward to $222.00 with an outperform rating. Berenberg Bank upgraded its rating from hold to buy, setting a new price target of $270.00, reflecting strong investor interest.

Overall, AbbVie currently holds an average rating of Moderate Buy among analysts, with an average price target of $223.45. The company continues to be a focal point in the pharmaceutical industry, driven by its diverse product offerings and robust market performance.

You May Also Like

Technology

Tesla (TSLA) recently reported a year-over-year drop in second-quarter deliveries, yet the market responded with optimism, pushing the stock up by 5%. This unexpected...

Health

The All England Lawn Tennis Club in London experienced its hottest-ever opening day on Monday, as the prestigious Wimbledon tournament kicked off under unprecedented...

Technology

In a bold reimagining of the DC Universe, director James Gunn has introduced a significant narrative element in his latest film, which reveals that...

Science

Look out, daters: a new toxic relationship trend is sweeping through the romantic world, leaving many baffled and heartbroken. Known as “Banksying,” this phenomenon...

Technology

Former Speaker of the House Nancy Pelosi has recently made headlines with her latest investment in the tech sector. According to official filings, she...

Entertainment

Netflix’s eagerly anticipated talent competition Building the Band is set to premiere on July 9, promising an emotional journey for viewers. This series, centered...

Entertainment

A new documentary series titled “Animals on Drugs” is set to premiere on the Discovery Channel on July 28, 2023. The three-part series follows...

Technology

The answer to today’s NYT Wordle, dated August 8, 2025, is the verb IMBUE. This word, which means “to fill or saturate,” features three...

World

The first dose of the hepatitis B vaccine is recommended at birth, a practice that has come under scrutiny following recent comments by Health...

Sports

ZAGREB, Croatia — A concert by Marko Perkovic, a right-wing Croatian singer known for his controversial views, attracted tens of thousands of fans to...

Technology

The Evo 2025 tournament is set to take place from August 1 to August 3, 2025, showcasing some of the most popular fighting games...

Sports

As the summer of 2025 unfolds, the video game industry is set to deliver a diverse array of new releases that promise to captivate...

Politics

Billionaire hedge fund manager Bill Ackman faced significant backlash following his professional tennis debut at the Hall of Fame Open in Newport, Rhode Island,...

Business

Erin Dana Lichy, a prominent cast member of “Real Housewives of New York,” has officially settled into her dream home, a grand townhouse located...

Lifestyle

The upcoming TRNSMT 2025 festival is set to take place from July 7 to July 9, 2025, at Glasgow Green, and organizers have released...

Entertainment

While the echoes of Summer Game Fest 2025 and the Xbox Games Showcase still resonate, Xbox has already set its sights on the next...

Copyright © All rights reserved. This website provides general news and educational content for informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the information presented. The content should not be considered professional advice of any kind. Readers are encouraged to verify facts and consult appropriate experts when needed. We are not responsible for any loss or inconvenience resulting from the use of information on this site.